Physician profile
Mark Wen Li
NPI 1356375059
$10,390.14
in general payments reported to CMS, 2019-2025
27 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,641 · 2020: $1,334 · 2021: $915 · 2022: $716 · 2023: $627 · 2024: $919 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Consulting Fee: $175 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.79 |
| Consulting Fee | $175.00 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,279.28 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $1,681.05 | 2019-2025 | Breztri |
| Amgen INC. | $1,402.22 | 2019-2025 | Prolia, Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $733.62 | 2019-2025 | Livalo, Zoryve |
| Phathom Pharmaceuticals, INC. | $528.32 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $517.49 | 2019-2021 | |
| Abbvie INC. | $424.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $305.34 | 2019 | |
| Sunovion Pharmaceuticals INC. | $270.83 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $226.89 | 2019-2025 | |
| Novo Nordisk INC | $177.56 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Iqirvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.42 | 2023 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.61 | 2019-2021 | |
| Astellas Pharma US INC | $82.86 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $70.23 | 2020-2021 | |
| Vivus LLC | $61.19 | 2019 | |
| Braintree Laboratories, INC. | $44.76 | 2021 | |
| Pfizer INC. | $44.55 | 2022 | |
| Allergan, INC. | $39.77 | 2020 | |
| Radius Health, INC. | $35.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.79 | 2019 | |
| Ferring Pharmaceuticals INC. | $26.19 | 2021 | |
| Neurelis, INC. | $23.74 | 2023 | Valtoco |
| Sun Pharmaceutical Industries INC. | $19.45 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.92 | 2020 | |
| Merck Sharp & Dohme LLC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.